LYPD3 - LY6/PLAUR domain containing 3 Gene

Also Known as C4.4A

Species: Homo sapiens

Gene Type: protein coding
Gene ID: 27076

About LYPD3

Cytogenetic location: 19q13.31 Genomic coordinates (GRCh38): 19:43,460,787-43,465,608 (from NCBI)

This gene has 4 transcripts (splice variants), 103 orthologues and 2 paralogues. Biased expression in esophagus (RPKM 319.1) and skin (RPKM 226.0).

Summary

Predicted to enable laminin binding activity. Predicted to act upstream of or within cell-matrix adhesion. Located in extracellular space. [provided by Alliance of Genome Resources, Apr 2022]

LYPD3 Products (1)

mRNA Protein Name
NM_014400.3 NP_055215.2 ly6/PLAUR domain-containing protein 3 precursor

Gene Ontology

  • Biological Process
Biological Process GO Annotation Evidence References Source
involved in negative regulation of smooth muscle cell apoptotic process IGI
IGI: Inferred from genetic interaction
32151690 GOA
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

LYPD3 Protein Structure

UPAR_LY6

UPAR_LY6: u-PAR/Ly-6 domain (33 - 83)

UPAR_LY6

UPAR_LY6: u-PAR/Ly-6 domain (140 - 222)

  • 0
  • 100
  • 200
  • 300
  • 346 a.a.
Protein Preferred Names Protein Names

ly6/PLAUR domain-containing protein 3

  • 2310061G07Rik

Recombinant LYPD3 Proteins

Cat. No. Product Name Accession Purity
HY-P70219 LYPD3/C4.4A Protein, Human (HEK293, His) O95274 (L31-H286) ≥ 95%, as determined by reducing SDS-PAGE.

LYPD3 Antibodies

Cat. No. Product Name Application Reactivity
HY-P81353 LYPD3 Antibody (YA1098) IHC-P Human
HY-P81353A LYPD3 Antibody (YA1098)(PBS only) IHC-P Human
HY-P81550 LYPD3 Antibody (YA1295) WB, IHC-P, ICC/IF, IP Human
HY-P86287 LYPD3 Antibody (YA5979) WB, IHC-P, IP Human

Related Diseases

Diseases Alias
Atrial Septal Defect 6

  • ASD6

  • Atrial Heart Septal Defect 6

  • Septal Defect, Atrial, Type 6
Mitochondrial Trifunctional Protein Deficiency

  • Tfp Deficiency

  • MTPD

  • Trifunctional Protein Deficiency

  • Trifunctional Protein Deficiency With Myopathy And Neuropathy

  • Tfpd

  • Familial Hypertrophic Cardiomyopathy

  • Cardiomyopathy Familial Hypertrophic

  • Familial Hcm

  • Heritable Hypertrophic Cardiomyopathy

  • Mtp Deficiency

  • Tpa Deficiency

  • Trifunctional Protein Deficiency, Type 2

  • Abetalipoproteinemia
Breast Cancer

  • Breast Carcinoma

  • Male Breast Cancer

  • Breast Cancer, Familial

  • Malignant Neoplasm Of Breast

  • Breast Cancer, Susceptibility To

  • Breast Cancer, Early-Onset

  • Malignant Tumor Of Breast

  • Carcinoma Of Male Breast

  • Breast Cancer, Invasive Ductal

  • Breast Cancer, Protection Against

  • Breast Cancer, Somatic

  • Breast Cancer, Male

  • Breast Cancer, Lobular, Somatic

  • Breast Tumor

  • Mammary Cancer

  • Mammary Tumor

  • Malignant Neoplasm Of Male Breast

  • Mammary Carcinoma

  • Male Breast Carcinoma

  • Familial Cancer Of Breast

  • Invasive Ductal Breast Carcinoma

  • Breast Cancer Susceptibility

  • Breast Cancer, Male, Susceptibility To

  • Breast Cancer, Early-Onset, Susceptibility To

  • Malignant Tumor Of The Breast

  • Mammary Neoplasm

  • Primary Breast Cancer

  • Neoplasm Of Male Breast

  • Carcinoma Of Breast

  • Breast Cancer In Men

  • Familial Breast Cancer

  • Cancer Of Breast

  • BC

  • Breast Cancer Familial

  • Breast Cancer Familial Male

  • Breast Cancer, Familial Male

  • Breast Male Carcinoma

  • Breast Neoplasms

  • Breast Neoplasms, Male

  • Mammary Tumors

  • Mammary Carcinomas

  • Cancer, Breast

  • Cancer, Breast, Susceptibility

  • Invasive Breast Ductal Carcinoma

  • Breast Neoplasm

  • Susceptibility To Breast Cancer

  • Mammary Neoplasms

  • Animal Mammary Neoplasms

  • Primary Malignant Neoplasm Of Breast

  • Infiltrating Ductal Carcinoma Of Breast

  • Infiltrating Duct Carcinoma Of Unspecified Site

  • Infiltrating Ductular Carcinoma Of Unspecified Site

  • Invasive Breast Carcinoma Of No Special Type

  • Microinvasive Carcinoma Of Breast

  • Carcinoma With Apocrine Differentiation
Diseases Alias
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Phase
HY-P99719 Lupartumab Amadotin 99.61% Phase 1
Inhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Phase
HY-P99718 Lupartumab 99.52% Phase 1

Pre-clinical Phase

Bioactive Molecules (4)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-147281 BAY 1135626 99.19% Unkown
HY-RS07917 LYPD3 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS17704 Lypd3 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS24168 Lypd3 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
Inhibitory Antibodies (1)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P992360 GT-002 Modulator / Unkown

Orthologs Information

Species Symbol Source ID
Felis catus LYPD3 VGNC VGNC:63341
Bos taurus LYPD3 VGNC VGNC:31101
Rattus norvegicus LYPD3 RGD RGD:69053
Mus musculus LYPD3 MGD MGI:1919684
Canis familiaris LYPD3 VGNC VGNC:42885
Others LYPD3 NCBI